StageZero Life Sciences (TSXV:SZLS.H) Research & Development: C$0.00 Mil (TTM As of Sep. 2024)


TSXV:SZLS.H StageZero Life Sciences Ltd TSXV:SZLS.H
10 GF Score
Price C$0.04
View Full Analysis

What is StageZero Life Sciences Research & Development?

StageZero Life Sciences TSXV:SZLS.H 10 Research & Development is C$0.00 Mil as of Sep. 2024. GuruFocus rates TSXV:SZLS.H with a GF Score™ of 10/100.

Research & Development is the aggregate amount of research and development expenses during the year. StageZero Life Sciences's Research & Development for the three months ended in Sep. 2024 was C$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.00 Mil.

StageZero Life Sciences  (TSXV:SZLS.H) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

StageZero Life Sciences Research & Development Related Terms

StageZero Life Sciences Research & Development Historical Data

* Premium members only.

The historical data trend for StageZero Life Sciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences Research & Development Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.28 0.99 0.48

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.03 0.00 0.00 0.00
TSXV:SZLS.H
10GF Score
StageZero Life Sciences Ltd TSXV:SZLS.H
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StageZero Life Sciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of C$0.00 Mil mean?
StageZero Life Sciences (TSXV:SZLS.H) has a Research & Development of C$0.00 Mil as of Sep. 2024. Research and development expense is the total cost for research and development activities. View historical data on StageZero Life Sciences and its competitors.
Is StageZero Life Sciences' Research & Development too high?
StageZero Life Sciences' current Research & Development is C$0.00 Mil. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' Research & Development compare to IDTA and TTOO?
StageZero Life Sciences' Research & Development of C$0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on StageZero Life Sciences and its competitors. StageZero Life Sciences's current Research & Development is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (TSXV:SZLS.H) has a current Research & Development of C$0.00 Mil. The current Research & Development is C$0.00 Mil. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For StageZero Life Sciences (TSXV:SZLS.H), the current Research & Development is C$0.00 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for TSXV:SZLS.H

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.04
Price